Venus Remedies has been awarded its first disbursement of Rs 7.50 crore under the Central government's Production Linked Incentive (PLI) scheme for the financial year 2022-23, which covers 75% of the total incentive due to the company for the year.
Having been selected as one of the few pharmaceutical companies under the PLI scheme in December 2021, the company has since embarked on a journey to amplify its manufacturing infrastructure and expand its product portfolio. The company has met the government's rigorous investment and sales criteria to qualify for the scheme. Venus Remedies belongs to the Category C of non-MSME pharmaceutical companies chosen under the PLI scheme. The disbursement will bolster the company's manufacturing capabilities and foster product diversification, including manufacturing of complex generics, in line with the vision of Atmanirbhar Bharat.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1797.80 |
Dr. Reddys Lab | 1213.90 |
Cipla | 1486.30 |
Lupin | 2069.95 |
Zydus Lifesciences | 948.70 |
View more.. |